US$ 26.53
foxo4-dri peptide senolytic study Buy UK | ≥98% Purity Frontiers | Senolytic Peptide FOXO4-DRI
Description
Both target similar pathways (growth factor signaling, tissue repair), but BPC-157 is more targeted, lower cost, and produces a more consistent response based on this data

HbA1c reduction and glucose control tracked with what you would expect from a semaglutide-based therapy, and the safety profile matched the broader GLP-1 class

Once your treatment cycle is complete, our team will guide you through what to expect and how to maintain your results

Choose food options
